Puyang Medical College, Henan, 457000, China.
Puyang People's Hospital, Henan, 457000, China.
Cardiovasc Toxicol. 2022 Sep;22(9):771-786. doi: 10.1007/s12012-022-09762-6. Epub 2022 Jul 25.
Cardiac remodelling is characterized by abnormal changes in the function and morphological properties such as diameter, mass, normal diameter of cavities, heart shape, fibrosis, thickening of vessels and heart layers, cardiomyopathy, infiltration of inflammatory cells, and some others. These damages are associated with damage to systolic and diastolic abnormalities, damage to ventricular function, and vascular remodelling, which may lead to heart failure and death. Exposure of the heart to radiation or anti-cancer drugs including chemotherapy drugs such as doxorubicin, receptor tyrosine kinase inhibitors (RTKIs) such as imatinib, and immune checkpoint inhibitors (ICIs) can induce several abnormal changes in the heart structure and function through the induction of inflammation and fibrosis, vascular remodelling, hypertrophy, and some others. This review aims to explain the basic mechanisms behind cardiac remodelling following cancer therapy by different anti-cancer modalities.
心脏重构的特征是功能和形态学特性的异常变化，如直径、质量、腔正常直径、心脏形状、纤维化、血管和心脏层增厚、心肌病、炎症细胞浸润等。这些损伤与收缩和舒张异常、心室功能损伤和血管重构有关，可能导致心力衰竭和死亡。心脏暴露于辐射或抗癌药物，包括化疗药物如多柔比星、受体酪氨酸激酶抑制剂（如伊马替尼）和免疫检查点抑制剂（ICI），可通过诱导炎症和纤维化、血管重构、肥大等，引起心脏结构和功能的几种异常变化。本综述旨在解释不同抗癌方式治疗癌症后心脏重构的基本机制。
